Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic

By Keck Jr Paul E   McElroy Susan L  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 4, 2003-04 ,pp. : 655-662

Informa Healthcare

Access to resources Recommend Favorite

Imaging extrastriatal dopamine D 2 receptor occupancy by endogenous dopamine in healthy humans

By Fujita M.   Verhoeff N.P.L.G.   Varrone A.   Zoghbi S.S.   Baldwin R.M.   Jatlow P.A.   Anderson G.M.   Seibyl J.P.   Innis R.B.  

European Journal of Pharmacology, Vol. 387, Iss. 2, 2000-01 ,pp. : 179-188

Elsevier

Access to resources Recommend Favorite

Effects of amphetamine challenge on local cerebral glucose utilization after chronic dopamine D 1 and D 2 receptor agonist administration to rats

By Huang Y.-H.   Tsai S.-J.   Huang H.-J.   Sim C.-B.  

European Journal of Pharmacology, Vol. 338, Iss. 2, 1997-11 ,pp. : 117-121

Elsevier

Access to resources Recommend Favorite

Prolactinemia is uncoupled from central D₂/D₃ dopamine receptor occupancy in amisulpride treated patients

By Bressan Rodrigo   Erlandsson Kjell   Spencer Edgar   Ell Peter   Pilowsky Lyn  

Psychopharmacology, Vol. 175, Iss. 3, 2004-09 ,pp. : 367-373

Springer Publishing Company

Access to resources Recommend Favorite

Discriminative stimulus properties of S32504, a novel D₃/D₂ receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D₂ but not D₃ receptors

By Millan Mark   Iob Loretta   Péglion Jean-Louis   Dekeyne Anne  

Psychopharmacology, Vol. 191, Iss. 3, 2007-04 ,pp. : 767-782

Springer Publishing Company

Access to resources Recommend Favorite